Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 8-(4-(3-(5-fluoro-1h-indol-3-yl)propyl)piperazin-1-yl)-4h-benzo(1,4)oxazin-2-methyl-3-one
2. Slv 314
3. Slv-314
4. Slv314
1. 327026-93-7
2. Slv-314
3. Lensiprazine [inn]
4. N47mw76ogx
5. Chembl196514
6. (r)-8-(4-(3-(5-fluoro-1h-indol-3-yl)propyl)piperazin-1-yl)-2-methyl-2h-benzo[b][1,4]oxazin-3(4h)-one
7. Unii-n47mw76ogx
8. Lensiprazine [who-dd]
9. Dtxsid60186379
10. Bdbm50176019
11. Zinc11689014
12. (2r)-8-[4-[3-(5-fluoro-1h-indol-3-yl)propyl]piperazin-1-yl]-2-methyl-4h-1,4-benzoxazin-3-one
13. 026l937
14. Q27284539
15. (2r)-8-(4-(3-(5-fluoro-1h-indol-3-yl)propyl)piperidin-1-yl)-2-methyl-2h-1,4-benzoxazin-3(4h)-one
16. (2r)-8-[4-[3-(5-fluoro-1h-indole-3-yl)propyl]piperazino]-2alpha-methyl-2h-1,4-benzooxazine-3(4h)-one
17. (r)-8-{4-[3-(5-fluoro-1h-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4h-benzo[1,4]oxazin-3-one
| Molecular Weight | 422.5 g/mol |
|---|---|
| Molecular Formula | C24H27FN4O2 |
| XLogP3 | 3.8 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 5 |
| Exact Mass | 422.21180428 g/mol |
| Monoisotopic Mass | 422.21180428 g/mol |
| Topological Polar Surface Area | 60.6 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 629 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Dopamine D2 Receptor Antagonists
Compounds and drugs that bind to and inhibit or block the activation of DOPAMINE D2 RECEPTORS. (See all compounds classified as Dopamine D2 Receptor Antagonists.)
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
A Lensiprazine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lensiprazine, including repackagers and relabelers. The FDA regulates Lensiprazine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lensiprazine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lensiprazine supplier is an individual or a company that provides Lensiprazine active pharmaceutical ingredient (API) or Lensiprazine finished formulations upon request. The Lensiprazine suppliers may include Lensiprazine API manufacturers, exporters, distributors and traders.
Lensiprazine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lensiprazine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lensiprazine GMP manufacturer or Lensiprazine GMP API supplier for your needs.
A Lensiprazine CoA (Certificate of Analysis) is a formal document that attests to Lensiprazine's compliance with Lensiprazine specifications and serves as a tool for batch-level quality control.
Lensiprazine CoA mostly includes findings from lab analyses of a specific batch. For each Lensiprazine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lensiprazine may be tested according to a variety of international standards, such as European Pharmacopoeia (Lensiprazine EP), Lensiprazine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lensiprazine USP).
LOOKING FOR A SUPPLIER?
